Company: RGNX
Filing Date: 2025-04-08
Form Type: DEF 14A
Source: 0000950170-25-052069
Chunk: 5

Company: REGENXBIO Inc.
Filing Date: 2025-04-08
Form: DEF 14A
Chunk 5
---
 filing of the first two sections of the rolling BLA for RGX-121.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Pipeline Prioritization and Corporate Restructuring                                          | We successfully implemented and completed our strategic pipeline prioritization and corporate restructuring announced in late 2023, which was designed to prioritize the development of ABBV-RGX-314, RGX-202 and RGX-121, while seeking strategic alternatives for our other clinical stage programs.We achieved our stated goal of strategic alternatives for our other clinical stage product candidates. We completed out-licensing agreements for RGX-181 for the treatment of late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease, and RGX-381 for the treatment of the ocular manifestations of CLN2 disease. In January 2025, we announced a strategic partnership to develop and commercialize RGX-121 and RGX-111 for the treatment of MPS II and MPS I, respectively, in the United States and Asia.We achieved our corporate objective of targeted cost reductions in excess of $50.0 million in 2024 stemming from the corporate restructuring plan implemented in late 2023. |
| Corporate Development and Pipeline Advancement                                               | We successfully transitioned senior leadership roles with the internal elevation of a newly appointed CEO and a new external hire of a CFO. Looking towards early portfolio plans, we continued to invest in our pre-clinical pipeline.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Financial Strength                                                                           | We ended 2024 with $244.9 million in cash, cash equivalents and marketable securities. In the first quarter of 2025, the Company announced a strategic partnership with Nippon Shinyaku to develop and commercialize RGX-121 and RGX-111, with a $110.0 million upfront payment received under the collaboration in March 2025.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |

<div align='center'>4</div>

Corporate Governance Highlights

Our commitment to effective corporate governance is illustrated by the following practices:

Our Board actively oversees and approves our corporate strategy.

Our Board and board committee agendas are structured to engage our directors in informed reviews of strategic and forward-looking issues.

Our Board reviews our enterprise-level risks and risk management practices.

The charters of the Board committees clearly establish the committees’ respective roles and responsibilities.

Our Board committees are fully independent.

We have a strong, independent, clearly defined lead independent director role with meaningful governance duties.

Our independent directors actively engage in board meetings,